Gerstein 2019 — REWIND Dulaglutide Cardiovascular Outcomes

The Lancet·July 13, 2019

Hertzel C. Gerstein, Heather M. Colhoun, Gilles R. Dagenais, REWIND Investigators

Summary

Dulaglutide reduced major adverse cardiovascular events during long-term follow-up in patients with type 2 diabetes.

Study Details

Study Design

Double-blind randomized placebo-controlled cardiovascular outcomes trial

Indication

Type 2 diabetes with or without previous cardiovascular disease

Intervention

Once-weekly dulaglutide vs placebo added to standard care

Species

Human

Sample Size

9,901 subjects

Risk of Bias Assessment

Sponsor-funded CVOT